Multi‐disciplinary collaborative consensus guidance statement on the assessment and treatment of breathing discomfort and respiratory sequelae in patients with post‐acute sequelae of SARS‐CoV ‐2 infection ( PASC )

作者：Jason H. Maley, George A. Alba, John T. Barry, Matthew N. Bartels, Talya K. Fleming, Christina V. Oleson, Leslie Rydberg, Sarah Sampsel, Julie K. Silver, Sabrina Sipes, Monica Verduzco‐Gutierrez, Jamie Wood, Joseph D. Zibrak, Jonathan Whiteson · 发表于：PM&R · 年份：2021 · DOI：10.1002/pmrj.12744 · 被引用次数：47 · 研究领域：Long-Term Effects of COVID-19、Psychosomatic Disorders and Their Treatments、COVID-19 and Mental Health

Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19), may experience lasting sequelae following the acute phase of their index infection.1 The post-acute sequelae of SARS-CoV-2 infection (PASC) can manifest as a wide-ranging constellation of disabling symptoms. These symptoms are sometimes referred to as being part of long COVID, post-acute COVID-19 syndrome, long-haul COVID, chronic COVID, or other terms, but for the purposes of this report, the term PASC will be used. Respiratory symptoms are among the most common symptoms reported by patients, and include shortness of breath, impaired exercise tolerance, cough, and chest pain.2-7 Although the incidence of PASC is not yet fully known, estimates suggest varying length of symptoms post-initial infection and expected recovery. In a study of patients with incident cases of COVID-19 in which individuals self-reported their symptoms prospectively in the COVID Symptom Study, a total of 558 participants (13.3%) reported symptoms lasting ≥28 days, 189 (4.5%) for ≥8 weeks, and 95 (2.3%) for ≥12 weeks.8 Persistent respiratory symptoms, in particular, may be more common among patients who required hospitalization, as dyspnea was present in 30% of previously hospitalized patients at 12-month follow-up in one longitudinal cohort.9 Despite the prevalence of these sequelae and emerging data on the longevity of symptoms, limited guidance exists reg...